Plain-English translation of NCT07308782 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new HIV medication called CL-197 to see how well it works at fighting the virus and how safe it is. Researchers will give people a single dose of the medication in one of three different amounts, then carefully watch how the body responds. This is an early-stage study to gather important safety and effectiveness information.
There is always a need for new HIV treatment options that work better, are easier to take, or have fewer side effects. This medication is being tested to see if it could become a helpful tool for people newly diagnosed with HIV.
You likely qualify if…
You likely don't qualify if…
You would receive a single dose of the experimental medication and then be closely monitored for about 13 days. During this time, you would visit the clinic for blood tests and other measurements to see how your body responds to the treatment and how the medication is processed. You would agree not to take any other HIV medications during this short study period while researchers gather safety and effectiveness information.
AI-generated summary from trial data · Aug 7, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Henan Genuine Biotech Co., Ltd.
Enrollment target
~24 participants
Started
November 2025
Primary completion
December 2026
Age range
18 Years – 60 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ping DU
Henan Genuine Biotech Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.